Opinion

Video

Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.

Video content above is prompted by the following:

  • Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
  • Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?
Related Videos
5 experts are featured in this series
5 experts are featured in this series
Christine Funke, MD
1 expert in this video
1 expert in this video
Dr Mingyang Song
Casey Koch, PharmD, sitting for a video interview
1 expert in this video
1 expert in this video
Dr John Heymach
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo